Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation

Vascular inflammation plays a crucial role in atherosclerosis, and its regulation is important to prevent cerebrovascular and coronary artery disease. The inflammatory process in atherogenesis involves a variety of immune cells including monocytes/macrophages, lymphocytes, dendritic cells, and neutrophils, which all express peroxisome proliferator-activated receptor-γ (PPAR-γ). PPAR-γ is a nuclear receptor and transcription factor in the steroid superfamily and is known to be a key regulator of adipocyte differentiation. Increasing evidence from mainly experimental studies has demonstrated that PPAR-γ activation by endogenous and synthetic ligands is involved in lipid metabolism and anti-inflammatory activity. In addition, recent clinical studies have shown a beneficial effect of thiazolidinediones, synthetic PPAR-γ ligands, on cardiovascular disease beyond glycemic control. These results suggest that PPAR-γ activation is an important regulator in vascular inflammation and is expected to be a therapeutic target in the treatment of atherosclerotic complications. This paper reviews the recent findings of PPAR-γ involvement in vascular inflammation and the therapeutic potential of regulating the immune system in atherosclerosis.

• Publication year

  2012

• Venue

  International Journal of Vascular Medicine

• Publication date

  2012-07-24

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1155/2012/508416PMID 22888436PMCID 3409528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disruption of Endothelial Peroxisome Proliferator-Activated Receptor &ggr; Accelerates Diet-Induced Atherogenesis in LDL Receptor-Null Mice

  2012cited by this paper
• Atherosclerosis: current pathogenesis and therapeutic options

  2011cited by this paper
• How dendritic cells shape atherosclerosis.

  2011cited by this paper
• Dendritic Cells in Human Atherosclerosis: From Circulation to Atherosclerotic Plaques

  2011cited by this paper
• CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice.

  2011cited by this paper
• Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis

  2011cited by this paper
• Neutrophilic granulocytes – promiscuous accelerators of atherosclerosis

  2011cited by this paper
• Dendritic cells in atherosclerosis: Functions in immune regulation and beyond

  2011cited by this paper
• Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

  2011cited by this paper
• Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity

  2011influential reference
• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  2010cited by this paper
• Natural IgM Antibodies Against Oxidation-Specific Epitopes

  2010cited by this paper
• Resident Intimal Dendritic Cells Accumulate Lipid and Contribute to the Initiation of Atherosclerosis

  2010cited by this paper
• PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice

  2010cited by this paper
• Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance.

  2010cited by this paper
• Kinetic Assessment and Therapeutic Modulation of Metabolic and Inflammatory Profiles in Mice on a High-Fat and Cholesterol Diet

  2010cited by this paper
• Phagocyte partnership during the onset and resolution of inflammation

  2010cited by this paper
• Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis

  2010cited by this paper
• Peroxisome Proliferator-Activated Receptor α and γ Agonists Together with TGF-β Convert Human CD4+CD25− T Cells into Functional Foxp3+ Regulatory T Cells

  2010cited by this paper
• Insiders criticise FDA’s decision not to withdraw rosiglitazone

  2010cited by this paper
• The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell–intrinsic fashion and suppresses CNS autoimmunity

  2009cited by this paper
• Immune and inflammatory mechanisms of atherosclerosis (*).

  2009cited by this paper
• Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

  2009cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Ligands Enhance Human B Cell Antibody Production and Differentiation1

  2009cited by this paper
• GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions

  2009cited by this paper
• PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice.

  2008cited by this paper
• Mechanisms of Disease: the evolving role of regulatory T cells in atherosclerosis

  2008cited by this paper
• Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis

  2008cited by this paper
• The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• B lymphocytes: how they develop and function.

  2008cited by this paper
• Cytokine-producing B lymphocytes-key regulators of immunity.

  2008cited by this paper
• Regulatory B cells as inhibitors of immune responses and inflammation

  2008cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature

  2008cited by this paper
• The 'short' history of regulatory B cells.

  2008cited by this paper
• Exploring the full spectrum of macrophage activation

  2008cited by this paper
• Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway.

  2008cited by this paper
• Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

  2007cited by this paper
• CX3CR1 Deficiency Impairs Dendritic Cell Accumulation in Arterial Intima and Reduces Atherosclerotic Burden

  2007cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Adipose Mitochondrial Biogenesis Is Suppressed in db/db and High-Fat Diet–Fed Mice and Improved by Rosiglitazone

  2007cited by this paper
• Macrophage-specific PPARγ controls alternative activation and improves insulin resistance

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Functional profile of activated dendritic cells in unstable atherosclerotic plaque

  2007cited by this paper
• PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism.

  2007cited by this paper
• 9-cis-Retinoic Acid (9cRA), a Retinoid X Receptor (RXR) Ligand, Exerts Immunosuppressive Effects on Dendritic Cells by RXR-Dependent Activation: Inhibition of Peroxisome Proliferator-Activated Receptor γ Blocks Some of the 9cRA Activities, and Precludes Them to Mature Phenotype Development1

  2007cited by this paper
• Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Immunoregulation: Enhancement of Regulatory T Cells through PPARγ-Dependent and -Independent Mechanisms

  2007influential reference
• Peroxisome Proliferator-Activated Receptor γ Control of Dendritic Cell Function Contributes to Development of CD4+ T Cell Anergy

  2007cited by this paper
• PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

  2007cited by this paper
• Thiazolidinediones and Heart Failure

  2007cited by this paper
• Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms.

  2007cited by this paper
• Transcription coactivators for peroxisome proliferator-activated receptors.

  2007cited by this paper
• Granulocyte Macrophage Colony-Stimulating Factor Regulates Dendritic Cell Content of Atherosclerotic Lesions

  2007cited by this paper
• Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor gamma agonist, and their contribution to GW7845-induced apoptosis.

  2006cited by this paper
• Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.

  2006cited by this paper
• To 'B' regulated: B cells as members of the regulatory workforce.

  2006cited by this paper
• PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function.

  2006cited by this paper
• Dendritic cells: translating innate to adaptive immunity.

  2006cited by this paper
• Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• PPARγ, a Lipid‐Activated Transcription Factor as a Regulator of Dendritic Cell Function

  2006cited by this paper
• Peroxisome Proliferator‐Activated Receptor α, δ, γ1 and γ2 Expressions are Present in Human Monocyte‐Derived Dendritic Cells and Modulate Dendritic Cell Maturation by Addition of Subtype‐Specific Ligands

  2006cited by this paper
• Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent

  2006cited by this paper
• A Case for Regulatory B Cells1

  2006cited by this paper
• Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation.

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.

  2005cited by this paper
• 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins.

  2005cited by this paper
• Hypochlorite-oxidized low-density lipoprotein upregulates CD36 and PPARγ mRNA expression and modulates SR-BI gene expression in murine macrophages

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Dendritic cells in atherosclerosis: current status of the problem and clinical relevance.

  2005cited by this paper
• The many faces of PPARgamma.

  2005cited by this paper
• 15-Deoxy- 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF- B activity and down-regulation of antiapoptotic proteins

  2005cited by this paper
• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia

  2005cited by this paper
• CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism.

  2005cited by this paper
• PPARs: therapeutic targets for metabolic disease.

  2005cited by this paper
• CD40 Engagement Prevents Peroxisome Proliferator-Activated Receptor γ Agonist-Induced Apoptosis of B Lymphocytes and B Lymphoma Cells by an NF-κB-Dependent Mechanism1

  2005cited by this paper
• A Case for Regulatory B Cells

  2005cited by this paper
• Peroxisome proliferator-activated receptor gamma in diabetes and metabolism.

  2004cited by this paper
• Functional plasticity of macrophages: reversible adaptation to changing microenvironments

  2004cited by this paper
• PPARs and the complex journey to obesity

  2004cited by this paper
• PPAR‐γ agonists as therapy for diseases involving airway neutrophilia

  2004cited by this paper
• Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques.

  2004cited by this paper
• Environmental and Endogenous Peroxisome Proliferator-Activated Receptor γ Agonists Induce Bone Marrow B Cell Growth Arrest and Apoptosis: Interactions between Mono(2-ethylhexyl)phthalate, 9-cis-Retinoic Acid, and 15-Deoxy-Δ12,14-prostaglandin J21

  2004cited by this paper
• Peroxisome proliferator-activated receptor γ in diabetes and metabolism

  2004cited by this paper
• PPAR-gamma agonists as therapy for diseases involving airway neutrophilia.

  2004cited by this paper
• Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

  2004cited by this paper
• Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells

  2004cited by this paper
• Degree of oxidation of low density lipoprotein affects expression of CD36 and PPARgamma, but not cytokine production, by human monocyte-macrophages.

  2003cited by this paper
• Alternative activation of macrophages

  2003cited by this paper
• Human B Lymphocytes and B Lymphomas Express PPAR-γ and Are Killed by PPAR-γ Agonists

  2002cited by this paper
• Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists.

  2002cited by this paper
• Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells*

  2002cited by this paper
• Peroxisome Proliferator-Activated Receptor Gamma Agonist Ligands Stimulate a Th2 Cytokine Response and Prevent Acute Colitis

  2002cited by this paper
• Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells.

  2002cited by this paper
• Peroxisome Proliferator-Activated Receptor -Mediated NF- B Activation and Apoptosis in Pre-B Cells

  2002cited by this paper
• Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors1

  2002cited by this paper
• PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis

  2002cited by this paper
• Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor γ1

  2002cited by this paper

• Immune system parameters in patients with chronic opistorchiasis based on genetic polymorphism associated with carbohydrate and lipid metabolism disorders

  2024cites this paper
• The nutritional value and health properties of tahini and tahini-based products

  2024cites this paper
• Effect of Exercise Training on Peroxisome Proliferator-Activated Receptor γ (PPAR-γ) Level: A Systematic Review

  2023cites this paper
• 6-Gingerol attenuates ventilator-induced lung injury via anti-inflammation and antioxidative stress by modulating the PPARγ/NF-κBsignalling pathway in rats.

  2021cites this paper
• Proteomic analysis detects deregulated reverse cholesterol transport in human subjects with ST-segment elevation myocardial infarction.

  2020cites this paper
• Matrix Metalloproteinase-12 Is Required for Granuloma Progression

  2020cites this paper
• Relation between resistin, PPAR-γ, obesity and atherosclerosis in male albino rats

  2020cites this paper
• PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury

  2019cites this paper
• The Role of Genetic Polymorphism in the Formation of Arterial Hypertension, Type 2 Diabetes and their Comorbidity.

  2019cites this paper
• Ginsenoside Rb1 ameliorates CKD‐associated vascular calcification by inhibiting the Wnt/β‐catenin pathway

  2019cites this paper
• High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification.

  2018cites this paper
• Adiponectin and Orexin-A as a Potential Immunity Link Between Adipose Tissue and Central Nervous System

  2018cites this paper
• Smooth muscle cell-specific deletion of Col15a1 unexpectedly leads to impaired development of advanced atherosclerotic lesions.

  2017cites this paper
• Heart and vascular remodeling in essential hypertension and type 2 diabetes is dependent on genetic polymorphisms

  2017cites this paper
• The effects of oleanolic acid on atherosclerosis in different animal models

  2017cites this paper
• Angiotensin II Type 2 Receptor Inhibits Vascular Intimal Proliferation With Activation of PPARγ.

  2016cites this paper
• The Crucial Relevance of ALA and LA as Primary Peroxisomal Beta-Oxidation Substrates, of Oxidised LA as the Primary Endogenous Activator of PPAR Gamma, and Energy Deficit as the Primary Activator of PPAR Alpha

  2016cites this paper
• A Sesame Seeds-Based Breakfast Could Attenuate Sub-Clinical Inflammation in Type 2 Diabetic Patients: A Randomized Controlled Trial

  2015cites this paper
• Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery.

  2015cites this paper
• The Role of Inflammation in Myocardial Infarction

  2014cites this paper
• Minireview: Challenges and opportunities in development of PPAR agonists.

  2014cites this paper
• Транскрипционная регуляция в патогенезе хронических заболеваний желудочно-кишечного тракта: роль рецепторов, активирующих пролиферацию пероксисом

  2014cites this paper
• Transient expression, purification and characterisation of human full-length PPARγ2 in HEK293 cells.

  2013cites this paper
• Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis

  2013cites this paper
• АКТИВИРУЮЩИХ ПРОЛИФЕРАЦИЮ ФИЗИОЛОГИИ ПАТОЛОГИИ ПОЧЕК PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN KIDNEY PHYSIOLOGY AND PATHOLOGY

  2013cites this paper
• Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis * Os receptores ativados pelo proliferador de peroxissoma (PPAR): uma perspectiva promissora na condução da psoríase e artrite psoriásica

  2013cites this paper